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Introduction
Methotrexate (MTX) is recommended for children with
juvenile idiopathic arthritis (JIA) with persistent oligoarti-
cular course with high disease activity and features of poor
prognosis or if they failed intraarticular glucocorticoid
steroid injections following the 2011 ACR recommenda-
tions for the treatment of JIA. To date efficacy and safety
of MTX for this JIA category have not been well studied.
Objectives
Evaluation of efficacy and safety of MTX in children
with oligoarticular persistent JIA.
Methods
Baseline demographics, clinical characteristics and disease
activity parameters have been prospectively documented
in the German JIA BIKER Register. Efficacy was deter-
mined using the PedACR response criteria and the
JADAS-10 until the last documentation or start of any
biologic agent. Safety assessments were based on adverse
events reports from the responsible physician.
Results
343 patients with a total of 2039 visits were identified
(894.7 total patient-years). 67% (n=231) were females.
The median age at JIA onset was 4.7 (quartile (Q) 25/75
2.5/9.2). At treatment initiation the median age was 8.0
years (Q25/75 4.3/12.0) and the disease duration 1.1
years (Q25/75 0.5/3.1). ANA positivity has been found
in 63.0%, HLB27 positivity in 11.1%. Prior MTX therapy
90.1% of children have been treated with nonsteroidal
anti-inflammatory drugs (NSAIDs), 46.1% have received
intraarticular glucocorticoid steroid injections. 88.3 of chil-
dren were treated concomitantly with NSAIDs, 11.5% with
corticosteroids and 2.6% with other disease-modifying
antirheumatic drugs.
A high proportion of patients showed a significant
response to treatment. Compared to baseline disease
activity parameters at MTX initiation, at month 6
70.5%/61.0%/41.5%, at month 12 73.9%/63.9%/43.5% and
at month 24 83.6%/80.0%/69.7% of patients met the
PedACR response criteria of 30%/50%/70%. The median
JADAS-10 at treatment start was 10.0 and decreased
markedly to 2.1 at month 6, 1.4 at month 12 and 1.0 at
month 24. At month 6 and month 12, 83 patients (33%)
and 96 patients (42%) reached preliminary criteria for
inactive disease.
113 patients experienced 216 adverse events (AE,24.7/
100 patient-years). Four were reported as serious (0.4/
100 patient-years (py)). The most common reported
AEs were nausea/vomiting (8.5/100 py), abnormal liver
enzymes (4.7/100 pj) and mild to moderate infections
(3.6/100 pj). 48 children (14%) suffered from uveitis
prior treatment. None of these patients flared with uvei-
tis. Four new uveitis index cases (1.1%) were reported
while on treatment.
37 patients started a biologic agent, 16 of them
switched from MTX to biologics while 21 patients were
treated in combination with MTX. Treatment has been
discontinued in 134 children for the following reasons:
Inefficacy 3.2%, adverse events 9.8%, remission 24.3%,
patients wish 16.5%, others 2.9%. 17 of 84 children
(20.2%) who stopped MTX because of remission flared
and re-started MTX.
Conclusion
Methotrexate appears to be highly effective in oligoarticu-
lar persistent JIA. The treatment is safe and well-tolerated.
Few patients discontinued due to intolerance or inefficacy.
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